Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19

Sunshine Biopharma Inc.

2024-Q1 EPS reported -$2.00 revenue$7,541,046

Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.
Net loss narrowed to $4,506,044 from $26,744,440; loss per share improved to -$0.19 from -$1.76.
Gross profit rose to $8,339,171 from $1,696,575; G&A expenses reduced to $13.1M from $28.7M.
Completed $5M private placement; repurchased 513,723 shares for $541,143.
Two proprietary drugs advanced to animal testing; IND-enabling studies for Adva-27a halted in November 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sunshine Biopharma Inc. reported the fiscal year ended December 31, 2023 results: revenue $ 24,092,787, net income $ 4,506,044, EPS negative $0.19 per share.

Period: the fiscal year ended December 31, 2023
Revenue: $ 24,092,787
Net income: $ 4,506,044
EPS: negative $0.19 per share
Result: reported results

Exact text from the filing

The following are key items contained in the Company’s Income Statement included in the 2023 10-K: 2023 2022 Sales $ 24,092,787 $ 4,345,603 Gross Profit $ 8,339,171 $ 1,696,575 General & Administrative Expenses $ 13,124,470 $ 28,697,325 Goodwill impairment $ – $ 18,326,719 Net Loss $ 4,506,044 $ 26,744,440

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.